Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

[1]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[2]  S. Loibl,et al.  Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Goldhirsch,et al.  Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. McLeod,et al.  CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1 , 2004, Therapeutic drug monitoring.

[5]  Mark J. Ratain,et al.  Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing , 2001, Investigational New Drugs.

[6]  P. Marquet,et al.  Pharmacokinetics of vinorelbine in man , 2004, European Journal of Clinical Pharmacology.

[7]  M. Guida,et al.  A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. , 2003, Clinical breast cancer.

[8]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Verweij,et al.  Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Grochow,et al.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.

[11]  David Miles,et al.  Combination versus sequential single-agent therapy in metastatic breast cancer. , 2002, The oncologist.

[12]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[13]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[16]  H. Burger,et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Puozzo,et al.  New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. , 2001, Journal of chromatography. A.

[18]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[19]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[20]  H. Kobayashi,et al.  CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  B. Reigner,et al.  Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients , 1999, Cancer Chemotherapy and Pharmacology.

[23]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ratain.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Levêque,et al.  Clinical Pharmacokinetics of Vinorelbine , 1996, Clinical pharmacokinetics.

[26]  W. Wargin,et al.  The clinical pharmacokinetics of vinorelbine (Navelbine). , 1994, Seminars in oncology.

[27]  P. Watkins.  Noninvasive tests of CYP3A enzymes. , 1994, Pharmacogenetics.

[28]  V. Vaitkevicius,et al.  Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer , 1974 .

[29]  E. Wolner,et al.  [On a simple relation between blood volume and body surface area]. , 1968, Zeitschrift fur Kreislaufforschung.